Processa Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Processa Pharmaceuticals, Inc. (PCSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 136.26 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-18
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-12-31 was 21.52K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 136.26K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 30.00K shares.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 129.92K shares, a 136.58% increase from fiscal 2018.
- Processa Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 54.91K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 136.26K shares 10-K · filed 2026-03-18 | ||||
| 2021-12-31 | 30.00K shares 10-K · filed 2023-03-30 | ||||
| 2021-06-30 | 17.80K shares 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | 129.92K shares 10-K · filed 2021-03-25 | ||||
| 2018-12-31 | 21.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | 54.91K shares 10-K · filed 2020-03-06 | 384.40K shares 10-K · filed 2019-03-28 | ||
| 2018-09-30 | 33.40K shares 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |